BENGALURU: University of Oxford researchers working in vaccine development effort to prevent Covid-19 have started screening healthy volunteers (aged 18-55) for their upcoming ChAdOx1 nCoV-19 vaccine trial in the Thames Valley Region.
The trial has been approved by UK regulators and ethical reviewers and interested candidates will have to volunteer for the programme.
The vaccine, the university said, is based on an adenovirus vaccine vector and the SARS-CoV-2 spike protein is already in production but won’t be ready for some weeks still.
“The team will enrol healthy volunteers aged between 18 – 55, who, if they pass screening, will be the first humans to test the new vaccine, called ChAdOx1 nCoV-19,” the varsity said in a statement.
The trial will provide valuable information on the safety acpects of the vaccine, as well as its ability to generate an immune responce of the virus.
The trial — collaboration between the University’s Jenner Institute and Oxford Vaccine Group clinical teams — will recruit up to 510 volunteers.
They will receive either the ChAdOx1 nCoV-19 vaccine or a control injection for comperision.
“Whilst the team will start screening people now to see if they are eligible to take part in the study, participant s will not recieve the vaccine for some weeks.” the statement added.
Detailed pre-clinical work is being done and the vaccine is being manufactured to clinical grade standard at the clinical Biomanufacturing facility at Oxford University.
Researchers are working as quickly as possible to get the vaccine ready to be used in the trial, which include further preclinical investigations and production of a larger number of doses of the vaccine.